<DOC>
	<DOCNO>NCT01077635</DOCNO>
	<brief_summary>Twice daily fosamprenavir , combination low dose ritonavir ( FPV/RTV BID ) , indicate treatment HIV-infected adult , adolescent child 6 year age use combination anti-HIV medicine . Safety data two GlaxoSmithKline ( GSK ) clinical trial ( APV29005 - involve twice-daily dos FPV without RTV APV20003 - daily dose FPV/RTV among 2-18 year old ) indicate gastrointestinal event commonly report AEs , majority event mild short duration . Treatment emergent grade 3 / 4 neutropenia report 20 % child APV20003 trial ; neutropenia identify potential safety concern European Medicines Agency ( EMEA ) . The objective study conduct observational cohort study usage safety FPV/RTV child adolescent ( age 6 â‰¤ 18 year ) HIV infection several European HIV paediatric cohort . Data collect 3 year ( 2008 , 2009 2010 ) .</brief_summary>
	<brief_title>PENTA Fosamprenavir Study</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>HIV1 infect child age 618 year expose licensed paediatric dose FPV/RTV January 1 2008 ( date exposure FPV early still expose 1/1/2008 ) participating cohort</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>protease inbitor</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>paediatrics</keyword>
</DOC>